Last updated on February 2020

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease


Brief description of study

This study consists of four parts, Parts A, B, C, and D. Part A is a single dose pharmacokinetic (PK) study in pediatric participants with Sickle Cell Disease. Part B is a multiple dose, safety, exploratory, efficacy, and PK study in adolescent Sickle Cell Disease participants who were 12-17 years of age. Part C is a multiple dose, safety, tolerability, and PK study, which includes the assessment of hematological effects and the effect on TCD flow velocity of voxelotor in pediatric participants with Sickle Cell Disease who are 4 to 17 years of age. Part D is a multiple dose, safety, tolerability, and PK study, which will examine the hematological effects of voxelotor in pediatric participants with Sickle Cell Disease who are between 9 months to < 4 years of age.

Clinical Study Identifier: NCT02850406

Find a site near you

Start Over

Dan Rudin, MD

Oakland, CA United States
  Connect »

Dan Rudin, MD

Chicago, IL United States
  Connect »

Dan Rudin, MD

Cleveland, OH United States
  Connect »

Dan Rudin, MD

Memphis, TN United States
  Connect »

Morgan Barnett

Atlanta, GA United States
  Connect »

Dan Rudin, MD

Kansas City, MO United States
  Connect »

Dan Rudin, MD

New Brunswick, NJ United States
  Connect »

Angela Martino

Pittsburgh, PA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.